Literature DB >> 22844379

Humoral and cellular immune responses to influenza vaccination in children with cancer receiving chemotherapy.

Rosa María Wong-Chew1, Margarita Nava Frías, Miguel Leonardo García-León, Lourdes Arriaga-Pizano, Aurora Medina Sanson, Constantino Lopez-Macías, Armando Isibasi, José Ignacio Santos-Preciado.   

Abstract

The immune response to influenza vaccination in children with cancer is controversial. The objective of this study was to characterize the cellular and humoral immune responses to an influenza vaccine in children with cancer who were receiving chemotherapy. In this study, children with cancer, who were not previously immunized, received an influenza vaccine via intramuscular injection. Blood samples were obtained prior to and at 4 weeks after immunization. Antibodies were measured using a hemagglutination inhibition (HI) assay. Cell-mediated immunity was measured by specific lymphoproliferation with (3)H-thymidine incorporation and by measuring cell frequencies following staining with monoclonal antibodies (CD8, CD4, CD19, CD45RA and CD27) using flow cytometry following incubation with the influenza antigen for 5 days. Geometric mean titers (GMT), mean counts per minute (cpm), cell frequencies prior to and following vaccination and percentage patient responses were compared using the Mann-Whitney non-parametric U and Chi-square tests; where p<0.05 was considered to indicate a statistically significant result. A total of 56 children were included. Their mean age was 6.64±3.61 years. Acute lymphoblastic leukemia (ALL) was diagnosed in 75, solid tumors in 23 and lymphoma in 2% of the children. Subjects with titers ≥40 hemagglutination units (HU) increased from 43% prior to vaccination to 73% following vaccination (p=0.01), whereas the GMT increased from 31.35 [95% confidence interval (CI), 29-111] to 143.45 HU (95% CI, 284-640) following vaccination (p<0.001). An increase in CD45RA expression in CD8(+) T cells was observed following vaccination (p=0.01). An increase in CD27 expression was observed in the CD4/8-negative cell population stimulated with the influenza antigen following vaccination (p<0.05). No serious adverse effects were observed. An increase in the seropositivity rate and GMT values following influenza vaccination were also observed. Influenza immunization was well tolerated among these children with cancer and increased the humoral and cellular immune responses with the activation of probable lymphoid precursors.

Entities:  

Year:  2012        PMID: 22844379      PMCID: PMC3402745          DOI: 10.3892/ol.2012.721

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Observations on excess mortality associated with epidemic influenza.

Authors:  T C EICKHOFF; I L SHERMAN; R E SERFLING
Journal:  JAMA       Date:  1961-06-03       Impact factor: 56.272

2.  Immunology. CD8alphaalpha and T cell memory.

Authors:  Sangwon V Kim; Richard A Flavell
Journal:  Science       Date:  2004-04-23       Impact factor: 47.728

3.  Clinical features of influenza.

Authors:  K G Nicholson
Journal:  Semin Respir Infect       Date:  1992-03

4.  The flu epidemic in Mexico: the challenges for doctors.

Authors:  Julio Sotelo; Rogelio Perez-Padilla
Journal:  BMJ       Date:  2009-05-05

5.  Immune response after influenza vaccination in children with cancer.

Authors:  Akinobu Matsuzaki; Aiko Suminoe; Yuhki Koga; Naoko Kinukawa; Koichi Kusuhara; Toshiro Hara
Journal:  Pediatr Blood Cancer       Date:  2005-11       Impact factor: 3.167

6.  Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection.

Authors:  Ron Keren; Theoklis E Zaoutis; Carolyn B Bridges; Guillermo Herrera; Barbara M Watson; Anna B Wheeler; Daniel J Licht; Xian Qun Luan; Susan E Coffin
Journal:  JAMA       Date:  2005-11-02       Impact factor: 56.272

Review 7.  Immunization of immunocompromised persons.

Authors:  David J Weber; William A Rutala
Journal:  Immunol Allergy Clin North Am       Date:  2003-11       Impact factor: 3.479

8.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

9.  Pandemic potential of a strain of influenza A (H1N1): early findings.

Authors:  Christophe Fraser; Christl A Donnelly; Simon Cauchemez; William P Hanage; Maria D Van Kerkhove; T Déirdre Hollingsworth; Jamie Griffin; Rebecca F Baggaley; Helen E Jenkins; Emily J Lyons; Thibaut Jombart; Wes R Hinsley; Nicholas C Grassly; Francois Balloux; Azra C Ghani; Neil M Ferguson; Andrew Rambaut; Oliver G Pybus; Hugo Lopez-Gatell; Celia M Alpuche-Aranda; Ietza Bojorquez Chapela; Ethel Palacios Zavala; Dulce Ma Espejo Guevara; Francesco Checchi; Erika Garcia; Stephane Hugonnet; Cathy Roth
Journal:  Science       Date:  2009-05-11       Impact factor: 47.728

10.  Estimating influenza hospitalizations among children.

Authors:  Carlos G Grijalva; Allen S Craig; William D Dupont; Carolyn B Bridges; Stephanie J Schrag; Marika K Iwane; William Schaffner; Kathryn M Edwards; Marie R Griffin
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

View more
  3 in total

1.  Immune response to influenza vaccination in children with cancer.

Authors:  Dimitrios Doganis; Athanasia Kafasi; Helen Dana; Nikolaos Spanakis; Margarita Baka; Apostolos Pourtsidis; Triantafyllia Sdogou; Artemis Vintila; Vaia Rafailidou; Panagiota Chantzi; Marina Servitzoglou; Despina Bouhoutsou; Maria Varvoutsi; Helen Kosmidis; Maria Tsolia
Journal:  Hum Vaccin Immunother       Date:  2018-06-08       Impact factor: 3.452

Review 2.  Protecting pediatric oncology patients from influenza.

Authors:  Leslie S Kersun; Anne F Reilly; Susan E Coffin; Kathleen E Sullivan
Journal:  Oncologist       Date:  2013-01-31

3.  Baseline CD3+CD56+ (NKT-like) Cells and the Outcome of Influenza Vaccination in Children Undergoing Chemotherapy.

Authors:  Evelin A Leibinger; Gábor Pauler; Noémi Benedek; Tímea Berki; István Jankovics; Richard McNally; Gábor Ottóffy
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.